Get started

Pennystocks

$IWM — Potential H&S forming on the 1hr We can either go lower to fill that open gap right off the bat... or We're going to go a bit higher to form the second shoulder, creating the H&S with a downside target of $193... Either way, that gap is filling — not sure if it will today, but likely for next week and for certain before March's 3rd Friday. The StochasticSlow is looking overbought, and the CCI is hinging lower just under that momentum line — bad sign for the bulls, if you ask me.
AMEX:IWMShort
by OptionsAddicts
1
Forecast | Penny Stock | LCINotes: I don't think the company will continue generating enough capital to sustain its operations, requiring them (1) to either take out more loans or (2) file for chapter 7/11 in the not too distant future. About the security: "Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA."
LShort
by UnknownUnicorn28743597
PKKFF should do a strong move next weekI have no position in this, but am keeping an eye on it. Time is running out on PKKFF and it should do a strong move soon but entering here is a gamble. -As the daily hull (highlighted) starts to crash into the price, it acts as resistance. -I see a pennant forming with the channel top as the resistance, likelihood of this being bearish is higher than a bullish reversal from what I've seen in other penny stocks. -Macd and stoch look like they will turn to the downside too. -I would not consider touching PKKFF until it can break that down channel and the daily hull. -However, buying on the bottom support of the channel can bring nice swing opportunities if you can time it right. -One bullish argument is the supertrend is a buy, it bounced on the 100 week EMA, and China stocks have been pretty good lately.
OTC:PKKFF
by Lynxys
WISH, is now a real penny stock as predicted on 13th Aug 2021!WISH can nicely be charted inside a down going parallel channel as shown! It is now a real penny stock as predicted several week ago! We offered an alternative bearish scenario when majority of technical analyst were bullish on WISH . We did not reject the possibility of bullish scenario and in fact, opened a long position based on that possible scenario but immediately closed our position with a tiny loss when our bullish scenario rejection condition met! Here is the publication: After a disappointing Earning Report we warned traders and investors : " This is not a buy chance ! " and WISH will be a penny stock : We always choose our stock smartly and trade objectively. Don't we?
W
by SaeedSajedi
4
EPAZ attractive valuation right, under 10M. Still undiscoveredEPAZ attractive valuation right now, well under 10M market cap, with that said it should go up way higher. from here They’re launching Bitcoincredit/debit cards plus they’re in other hot sectors NFTs , CBD , Metaverse and making serious noise. EPAZ trading at such a low market cap. Most good crypto + metaverse + crypto stocks are trading at a 30M-50M market cap. Plenty of upside for $EPAZ here pretty much, it’s still very early #pennystocks #stockmarket #stocks #BTC ZenaPay Blockchain Bitcoin wallet will include credit cards/debit cards to the user wallet. The user will be able to store both fiat currency and cryptocurrency. This will be a major upgrade to the ZenaPay wallet. We are providing additional support to new cryptocurrencies. We are working towards gasless transactions and providing easy transfer to traditional bank accounts. Our primary mission is to become an alternative to bank checking accounts for businesses and allowing them to earn money from their investment into cryptocurrency. As we build out the infrastructure more opportunities will begin to arise. Epazz CEO Shaun Passley, PhD, stated, "We are creating technology for the next generation of payment solutions." Future ZenaPay upgrades to be released soon. ZenaPay (www.zenapay.com) is being developed to solve a major problem in high-risk industries. Traditional banking systems do not allow high-risk industries to access their payment systems. ZenaPay offers a cutting-edge payment solution that gives consumers a way to buy items online or in stores using Bitcoin. The new Bitcoin payment software will allow consumers to use digital currency to make online or in-store purchases with ease. The process will also be anonymous because all transaction details are encrypted through Bitcoin, which will enable stores to accept digital currency instead of only cash. ZenaPay is available on the App Store and Play Store. About Epazz, Inc. (www.epazz.com) Epazz, Inc. is a leading cloud-based-software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions and the public sector. Epazz BoxesOS™ v3.0 is the complete business web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies and higher-education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz's other products are DeskFlex™ (a room scheduling software) and DeskFlex™ (an applicant-tracking system).
OTC:EPAZLong
by Bitplaza
Shiny Materials Penny Stocks fadingHi followers, After a long period of time, I finally get back on track to update some TA. In this January, I will highlight a few potential stocks to be considered. For those of you that hold these two penny stocks. They have both MA crossover on 17 Dec, hold your fire now since they almost hit the ceiling. SYR has a few bearish candlesticks signals, beware of the bomb! VectorVest values (10-Jan-2022) Mincor Rsrcs NL MCR RT = 1.76 RS = 0.93 VST = 1.24 CI = 1.23 REC = Buy Syrah Rsrcs SYR RT = 1.77 RS = 0.91 VST = 1.30 CI = 1.07 REC = Buy
M
by SoloTraderAU
$RBSH 350k Mrkt Cap, 9mil Float, Completed Turnaround Last Month$RBSH This has a 9mil Float, MM's walked it down on low Vol after a recent RS... Volume has come back with over 10x the 10Day Ave Vol, Accumulation out the roof, all indicators pointing to breakout soon... The Co just Completed a turnaround, New Officers Juts took over along with Ticker & Name Change...( Formerly Inspyr Therapeutics, now Rebus Holdings Inc ) They have Clinical Updates Coming, multiple patents, and also just reacquired some additional patents. See Link Below 15 U.S Patents, 40 Pending World Wide Applications - Clinical Trials Happening Currently - Google - inspyr-therapeutics-announces-holding-company-110000130 (Sorry, Can not post Link) So understand this - For this to have a $40 Million Market Cap which it did in 2021 - Now with the current SS, the price of $RBSH needs to be at $4 - Currently at $0.04 Cents = 1000% Up from here. No pumping needed, look into Inspyr. - FDA Meeting Held 2021 - Clinical Updates Coming - Inspyr had a market cap of 100 Million - Current market cap =350,000 - OS is 10 Million - Float - 9 Million Took positions .035-.04 so far, will add on .05 Break inspyrtherapeutics dot com rebus-corp dot com Patents + FDA Clinical Trials - Developing targeted cancer therapeutics that delivers a potent, unique & patented drug that directly treats breast, prostate, bladder, kidney, and lung cancer. Inspyr Therapeutics, Inc. is an integrated clinical-stage biopharmaceutical company focused on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer based on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark, Inspyr has a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. The pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types. The company involves in the discovery and development of pro-drug cancer therapeutics. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its pro-drug development candidates include G-202, which is in Phase I clinical trials and targets the blood vessels of various solid tumors; and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for the treatment of prostate cancer.
OTC:RBSHLong
by HDOGTX
BRGO Logscale Bullish ButterflyThe PCZ here is massive and because of that overall i wont be dedicating much of my account to this trade since this is a dangerous penny stock that shows no promise other than the potential logscale harmonic pattern presented on the chart; I personally will buy $500 worth at the 1.272, another $750 at the 1.414, and a final $1000 worth at the 1.618. I dont plan on using a stoploss for this trade which is why the amount i m going to invest is so low but in either case that's still alot of share so it's worth a shot.
OTC:BRGOLong
by RizeSenpai